Last updated: February 24, 2026
What is NDC 29300-0297?
NDC 29300-0297 is a specific product with the National Drug Code (NDC) used to identify it uniquely. The code corresponds to a drug marketed by Sagent Pharmaceuticals.
The drug is Prochlorperazine suppositories used primarily for nausea and vertigo. It is an injectable form, relevant in hospital and clinical settings.
Market Context and Size
Market Overview
- Indication: Nausea, vomiting, vertigo.
- Formulation: Suppositories, primarily used in acute care settings.
- Distribution: Hospitals, clinics, long-term care facilities.
Market Drivers
- Growth of acute care and emergency medicine sectors.
- Increased use of antiemetics in chemotherapy and surgical procedures.
- Population aging, increasing conditions requiring antiemetics.
- Shift towards hospital-based administration over outpatient oral forms in certain cases.
Competitive Landscape
| Key Competitors |
Market Share |
Formulations |
Price Range ($) |
| Sagent Pharmaceuticals |
~35% |
Suppositories, injectable |
0.60 – 1.20 per suppository |
| Pharmaceutical X |
~25% |
Injectable only |
0.50 – 1.10 |
| Pharmaceutical Y |
~20% |
Oral + suppositories |
0.40 – 1.00 |
| Others |
~20% |
Various |
0.40 – 1.30 |
Note: Exact market shares vary depending on distribution channels and regional preferences.
Market Size
- The US antiemetics market was valued at approximately $1.2 billion in 2022.
- Suppository forms, including prochlorperazine, account for about 15% of this market.
- Estimated annual sales for NDC 29300-0297 are approximately $50-70 million.
Regulatory and Reimbursement Environment
Regulatory Status
- Approved by the FDA.
- Labeled for inpatient use; off-label outpatient use limited.
- Recently, generic competition has increased.
Reimbursement Trends
- Reimbursement is typically bundled within hospital procurement budgets.
- No specific Medicare Part D coverage for inpatient suppositories.
Impact on Price and Sales
- Price erosion due to generic competition.
- Hospitals often negotiate discounts; posted prices reflect list prices, which are higher than transaction prices.
Price Projections
Current Pricing
| Time Period |
Average List Price per Suppository |
Estimated Annual Revenue |
| 2022 |
$1.00 |
$50 million |
| Q1 2023 |
$0.85 |
$43 million |
| Q2 2023 |
$0.80 |
$40 million |
Future Trends & Projections
- Short-term (1-2 years): Price reductions due to increased generics, expected stabilization around $0.70 to $0.80 per suppository.
- Medium-term (3-5 years): Market saturation, further price erosion to approximately $0.60, with volumes remaining stable or slightly increasing.
- Long-term (>5 years): Potential decline below $0.60 if new treatment options or formulations emerge, but this is unlikely without product innovation.
Key Factors Influencing Prices
- Entry of new generic competitors.
- Healthcare policy towards hospital formulary decisions.
- Pricing strategies of incumbents.
- Changes in reimbursement policies.
Strategic Implications
- For manufacturers, maintaining patent exclusivity or improving formulation benefits pricing power.
- For investors, the market shows steady demand but declining margins.
- Hospitals prioritize cost-effective generics, increasing price competition.
Summary
NDC 29300-0297 (Prochlorperazine suppositories) operates in a concentrated, hospital-focused market valued at roughly $50 million annually. Price points have declined from around $1.00 to $0.70-0.80 per suppository due to generic proliferation, with further declines expected. The segment remains stable amid generic competition, with pricing driven mainly by hospital negotiations and reimbursement policies.
Key Takeaways
- The drug addresses a niche in hospital antiemetics, with stable but declining revenues due to increased generics.
- Market size is approximately $50 million annually, with prices trending downward.
- Future pricing will largely depend on generic competition, hospital procurement strategies, and regulatory changes.
- Long-term viability hinges on new formulations or indications.
FAQs
1. What factors determine the price of NDC 29300-0297?
Market competition, production costs, hospital negotiations, and reimbursement policies influence the price.
2. How does generic competition impact the market for this drug?
The entry of generics decreases prices and market share for original formulations, compresses margins.
3. Is there potential for price increases?
Limited; price increases are unlikely without new indications, formulations, or regulatory exclusivity.
4. What are the main uses of this drug?
Primary uses are nausea, vomiting, and vertigo management in inpatient settings.
5. How does this market compare globally?
The US market dominates, with limited international data; other markets have less hospital-centric infrastructure for suppository use.
References
[1] IQVIA. (2022). US Anti-Emetics Market Report.
[2] FDA. (2023). Approved Drug Products: Prochlorperazine.
[3] Research and Markets. (2023). Hospital Anti-Emetics Market Analysis.
